This guidance will fully update the following:
Status In progress
Developed As CG

Provisional Schedule

Scoping workshop: 31 July 2015
Consultation on draft scope with stakeholders: 8 July - 5 August 2015
Draft guidance consultation 02 January 2018 - 12 February 2018
Expected publication June 2018

Project Team

Developer NICE Clinical Guidelines Team

Email enquiries


Key events during the development of the guidance:

Date Update
12 April 2017 Stakeholder list updated
06 April 2017 Committee list updated
12 September 2016 Committee meeting
06 May 2016 Consultation comments published
27 April 2016 Equality impact assessment published
08 February 2016 - 07 March 2016 Addendum consultation
08 February 2016 We are currently updating our guideline on Dementia: supporting people with dementia and their carers in health and social care (CG42). This update will incorporate the technology appraisal (TA) on Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (TA217). It has been agreed to separately update the first and third bullets of recommendation 1.3 of the TA The updated sections of the recommendation will be published separately as an addendum to TA217. When the full update of CG42 is produced, this addendum will then be incorporated into the guideline.
21 January 2016 Scope published
08 July 2015 - 05 August 2015 Draft scope consultation
11 September 2015

The Developer may make a focused call for evidence on specific clinical questions or sub-questions after completing its initial searches. It is able to make a call for evidence at any point during development of the guideline and stakeholders are usually given 4weeks to respond. The Developer will ask all registered stakeholders for this evidence.

The Developer may not issue any calls for evidence for a guideline if the Committee feels it is not necessary.

The Economic plan, review questions and search strategies will be available on the website 5 weeks before the draft guideline consultation starts.

08 September 2015

The final scope defines what the guideline covers. Comments from stakeholders on the draft scope can be seen in the draft scope consultation comments table.

The Committee looks at the evidence and develops the recommendations in the guideline.

05 August 2015

Consultation on the draft scope is complete and the scope is being modified in the light of the comments. The final scope will be posted here. It will define what the guideline will cover.

We are in the finalising details for developing the guideline, including the membership of the Committee and timescales.

08 July 2015

We are consulting on the draft scope for this guideline and recruiting Committee members between 8 July and 5 August 2015.

The scope defines what the guideline will cover. We want to hear your views.

The Committee looks at the evidence and develops the recommendations in the guideline. We are looking for specialists in the topic, people working in health and social care more generally (such as GPs) and commissioners, and people using health and care services and/or carers or advocates, and people from communities affected by the guideline.

For more information see Developing NICE guidelines: how to get involved.

19 June 2015

The first draft of the scope is being prepared. The scope will define what the guideline will cover.

18 May 2015

We have commissioned the Internal Clinical Guidelines Centre to update the guideline on Dementia which was published in November 2006. For further information on updating guidelines please see Developing NICE guidelines: the manual.

For further information on the guideline development process, please read how we develop NICE guidelines